Denosumab-Teva onco 120 mg / 1.7 ml, Injektionslösung

7680701320015 CH-70132 Injektionslösung

Associated product:

DENOSUMAB TEVA onco 120 mg / 1.7 ml sol inj

No image available

Article details

Package size
1
Selling units
1
Measure
Durchstechflasche(n)
Galenic form
Injektionslösung
Galenic group
Injektion/Infusion

Official Swissmedic V2 data

Additional information from the official database

Official medical documents

Summary of Product Characteristics
Allemand
24/09/2026
Summary of Product Characteristics
Français
24/09/2026
Summary of Product Characteristics
Italien
24/09/2026

Detailed composition

Substance Quantity Type Category
denosumabum
120.0 MG Substance Wirkstoff (Principe actif)
natrii acetas trihydricus
- Substance HNIDK
natrium
0.49 MG Substance HBESI
acidum aceticum glaciale
- Substance HNIDK
sorbitolum
79.9 MG Substance HBESI
polysorbatum 20
- Substance HNIDK
aqua ad iniectabile
- Substance HNIDK

Reimbursement information

Public price
CHF 210.45
Specialties list
Yes
Generic
No

Reimbursement limitation

SL addition date: 01/03/2026

Authorization holder

Teva Pharma AG

4051 Basel

Authorization information

Swissmedic authorization number
70132
Drug name
Denosumab-Teva onco, Injektionslösung
Galenic form
LSINJ
ATC Code
M05BX04
Authorization status
Z
Dispensing category
A
First authorization
10/12/2025
Authorization expiration date
09/12/2030
IT Number
07.16.1.
Domain
Human medicine
Field of application
Knochenmetastasen solider Tumoren; Riesenzelltumoren des Knochens

Package details

Description (FR)
DENOSUMAB TEVA onco 120 mg / 1.7 ml sol inj
Description (DE)
DENOSUMAB TEVA onco 120 mg / 1.7 ml Inj Lös
Market launch
01/03/2026
Narcotic (BTM)
No

Other package sizes (1)

None
3 DUR
GTIN: None
Not in V1
Buy us a coffee Explore the data